Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: Am J Kidney Dis. 2008 Nov 20;53(1):121–128. doi: 10.1053/j.ajkd.2008.08.010

Table 3. Power comparisons for completed clinical trials, and FAVORIT.

Study Event rate controls Power for 10% reduction in events Power for 15% reduction in events Power for 20% reduction in events
NORVIT7 0.182 0.16 0.33 0.54
Hope-29 0.198 0.46 0.81 1.00
VISP11 0.171 0.27 0.55 0.81
SWISS Heart10 0.228 0.08 0.14 0.23
Wrone et al12 0.417 0.10 0.18 0.31
CHAOS II*6 0.100 0.10 0.18 0.30
ASFAST13 0.541 0.13 0.26 0.43
HOST**8 0.238 0.24 0.48 0.73
WAFACS*5 0.148 0.33 0.65 0.89
FAVORIT***20 0.186 0.32 0.63 0.88

Note: Event rates in the control group are the observed event rates for all studies except FAVORIT. For FAVORIT, the event rate is the projected event rate from the protocol.

*

Event rates not given by treatment group; total event rate divided by 2

**

Event rates for fatal and non-fatal MI, fatal and non fatal stroke, and amputation, pooled

***

Not observed data; based on design